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PIN19 A RETROSPECTIVE EVALUATION OF THE MANAGEMENT AND OUTCOMES IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN AN INNER-CITY HOSPITAL
Sakalis
Pfizer Inc, Syosset, NY, USA OBJECTIVES: This study evaluated the medical management of patients hospitalized with Community Acquired Pneumonia (CAP) in an inner-city hospital comprising over 90% of Medicaid and indigent patients. The goal was to identify opportunities for quality improvement. METHODS: A random sample of patients with a diagnosis of CAP at discharge in 2002 was selected for retrospective chart review. Data was collected based on American Thoracic Society (ATS) criteria. RESULTS: Medical records of 155 patients were reviewed; mortality rate was 4%.
The percentage of patients receiving the first antibiotic dose in less than eight hours was 80. Ninety-seven percent of patients had oxygenation checked within 24 hours of admission. Only 45% of patients had blood cultures performed, and 91% of these were positive. The most common antibiotic prescribed was oral levofloxacin representing 39% of all antibiotic orders. Using the ATS guidelines, 14 patients (9%) were considered to have received inappropriate antimicrobial treatment. Of these, 7 had severe cases of CAP requiring treatment in the Intensive Care Unit (ICU). The most common cause for non-compliance in the ICU was lacked of coverage for atypical microbes. The average length of stay for all patients in the study was 7.64 days (SD +/-0.327). Patients who received a antibiotic regimen which complied with guidelines, as compared to those who did not, had a shorter length of study in the hospital (7.33 days vs 9.79 days, p = 0.31). CONCLUSION: Ongoing analysis will provide further improvement in clinical outcomes and will identify areas of focus for future research. Contemporary community-acquired pneumonia (CAP) guidelines recommend that intensive care unit (ICU) patients empirically receive a beta-lactam plus a macrolide (BLM) or a beta-lactam plus a fluoroquinolone (BLF). This study compares the impact of the initial antibiotic choice on time to clinical stability (TTCS), time to switch therapy (TTST), length of hospital stay (LOS), and in-hospital mortality. METHODS: Patient demographics, laboratory and physical exam findings, empiric antibiotic therapy, and hospital course (over 200 variables in all) were extracted from the medical records of all adult CAP patients admitted to the ICUs of 5 community hospitals between 1 November 1999 and 30 April 2000. Patients were divided into two groups (BLM and BLF) based on antibiotics received within the first 24h of hospitalization. TTCS, TTST, LOS and in-hospital mortality were compared using regression models that included the outcome as the dependent variable, antibiotic therapy as the independent variable, and Pneumonia Severity of Index (PSI score) as a covariate. RESULTS: Overall, there were 129 ICU patients of which 34% received BLF and 13% received BLM. Groups were similar with respect to age, sex, comorbidities, PSI score, pre-admission antibiotics, shock, acute renal failure, and the need for mechanical ventilation. Compared to patients who received BLM, those who received BLF had a significantly longer (median; OR, 95%CI) TTCS (2 vs. 4 days; 1.54, 1.04-2.20), TTST (6 vs. 10 days; 1.47, 1.06-2.00), and LOS (6.5 vs. 12 days; 1.58, 1.11-2.11). In-hospital mortality was similar between patients who received BLM and BLF (13% vs. 15%; 1.17, 0.23-8.95 ). CONCLUSION: Severe CAP patients who initially received a beta-lactam plus a macrolide had a faster time to clinical stability, shorter time to switch therapy, and reduced time to hospital discharge compared to patients treated with a beta-lactam plus a fluoroquinolone.
PIN20 COMPARISON OF HEALTH OUTCOMES AMONG SEVERE COMMUNITY-ACQUIRED PNEUMONIA PATIENTS TREATED EMPIRICALLY WITH A BETA-LACTAM PLUS A MACROLIDE VERSUS A BETA-LACTAM PLUS A FLUOROQUINOLONE
